Overview of this Product Guide

The following guide provides an overview of the COVID-19 therapeutics products allocated by Texas DSHS, including their availability, request methods, reporting requirements, shipping timelines, and helpful resources.

Note: We receive new information and system changes frequently. Please review the DSHS therapeutics website for regular updates. You can also subscribe to DSHS’ weekly Therapeutics eNewsletter by emailing therapeutics@dshs.Texas.gov.

In order to request therapeutics, you must first be enrolled for the specific therapeutic product you’re interested in. View the COVID-19 Therapeutics Enrollment Guide for details.
# Table of Contents

1. Therapeutics Product Overview
   A. Bebtelovimab
   B. Molnupiravir
   C. Paxlovid
   D. Evusheld
   E. Sotrovimab
   F. Bam/Ete
   G. REGEN-COV
   H. Reporting Requirements
   I. How to Request Therapeutics

2. Provider Tools
Below you can find a list of the COVID-19 Therapeutics products distributed by DSHS:

<table>
<thead>
<tr>
<th>Therapeutic Name</th>
<th>Request Method</th>
<th>Order in Multiples of</th>
<th>Manufacturer Contact Information</th>
<th>Fact Sheets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bebtelovimab</td>
<td>Email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a></td>
<td>10 courses</td>
<td>1-855-545-5921</td>
<td>Healthcare Providers, Recipients and Caregivers</td>
</tr>
<tr>
<td>Molnupiravir</td>
<td>Email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a></td>
<td>24 courses</td>
<td>1-800-444-2080</td>
<td>Healthcare Providers, Recipients and Caregivers</td>
</tr>
<tr>
<td>Paxlovid</td>
<td>Email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a></td>
<td>20 courses</td>
<td>1-800-438-1985</td>
<td>Healthcare Providers, Recipients and Caregivers</td>
</tr>
<tr>
<td>Evusheld</td>
<td>Email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a></td>
<td>24 cartons (1 carton = 150 mg tixagevimab plus 150 mg cilgavimab)</td>
<td>1-800-236-9933</td>
<td>Healthcare Providers, Recipients and Caregivers</td>
</tr>
</tbody>
</table>
The following products are no longer FDA authorized. Please review the most recent [DSHS communication](#):

<table>
<thead>
<tr>
<th>Therapeutic Name</th>
<th>Type/Form Details</th>
<th>Manufacturer</th>
<th>Manufacturer Contact Information</th>
<th>Fact Sheets</th>
<th>VAOS Ordering Request</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bam/Ete</td>
<td>IV Infusion</td>
<td>Eli Lilly</td>
<td>1-855-545-5921</td>
<td>- Healthcare Providers - Recipients and Caregivers</td>
<td>No (Ordering Paused)</td>
<td>Request Only</td>
</tr>
<tr>
<td>REGEN-COV</td>
<td>IV Infusion or subcutaneous injection</td>
<td>Regeneron</td>
<td>1-844-734-6643</td>
<td>- Healthcare Providers - Recipients and Caregivers</td>
<td>No (Ordering Paused)</td>
<td>Request Only</td>
</tr>
<tr>
<td>Sotrovimab</td>
<td>IV Infusion</td>
<td>GSK</td>
<td>1-866-475-2684</td>
<td>- Healthcare Providers - Recipients and Caregivers</td>
<td>Yes</td>
<td>Limited availability</td>
</tr>
</tbody>
</table>
## Bebtelovimab

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Administration Type</td>
<td>Intravenous injection over 30 seconds</td>
</tr>
<tr>
<td>Availability</td>
<td>Providers enrolled to received bebtelovimab can email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a> to request courses in the next coming allocation. Requests must be in multiples of five (5) with a minimum order of ten (10).</td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>Daily reporting to HPOP of number of courses dispensed and on-hand. Patient-level reporting to ImmTrac2 within 30 days of administering.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resource</th>
<th>Link/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider Fact Sheet</td>
<td><a href="https://www.fda.gov/media/156151/download">https://www.fda.gov/media/156151/download</a></td>
</tr>
<tr>
<td>FDA FAQ</td>
<td><a href="https://www.fda.gov/media/156154/download">https://www.fda.gov/media/156154/download</a></td>
</tr>
<tr>
<td>Lilly COVID Hotline</td>
<td>1-855-545-5979</td>
</tr>
</tbody>
</table>
# Lagevrio (molnupiravir)

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Administration Type</td>
<td>Oral</td>
</tr>
<tr>
<td>Availability</td>
<td>Pharmacies enrolled to dispense Lagevrio can email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a> to request courses in the next coming allocation. Requests must be in multiples of 24 courses.</td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>Daily reporting to HPOP of number of courses dispensed and on-hand Patient-level reporting to ImmTrac within 30 days of dispensing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resource</th>
<th>Link/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider Fact Sheet</td>
<td><a href="https://www.fda.gov/media/155054/download">https://www.fda.gov/media/155054/download</a></td>
</tr>
<tr>
<td>FDA FAQ</td>
<td><a href="https://www.fda.gov/media/155056/download">https://www.fda.gov/media/155056/download</a></td>
</tr>
<tr>
<td>Molnupiravir Site</td>
<td><a href="https://www.molnupiravir-us.com/hcp/">https://www.molnupiravir-us.com/hcp/</a></td>
</tr>
<tr>
<td>Merck Contact</td>
<td>1-800-444-2080</td>
</tr>
</tbody>
</table>
## Paxlovid

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Administration Type</td>
<td>Pills</td>
</tr>
<tr>
<td>Availability</td>
<td>Pharmacies enrolled to dispense Paxlovid can email <code>therapeutics@dshs.Texas.gov</code> to request courses in the next coming allocation. Requests must be in multiples of 20 courses.</td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>Daily reporting to <a href="https://www.fda.gov">HPOP</a> of number of courses dispensed and on-hand Patient-level reporting to <a href="https://www.fda.gov">ImmTrac</a> within 30 days of dispensing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resource</th>
<th>Link/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider Fact Sheet</td>
<td><a href="https://www.fda.gov/media/155050/download">https://www.fda.gov/media/155050/download</a></td>
</tr>
<tr>
<td>FDA FAQ</td>
<td><a href="https://www.fda.gov/media/155052/download">https://www.fda.gov/media/155052/download</a></td>
</tr>
<tr>
<td>Pfizer Medical Information</td>
<td><a href="http://www.pfizermedicalinformation.com">www.pfizermedicalinformation.com</a></td>
</tr>
<tr>
<td>Paxlovid Health Care Provider Site</td>
<td><a href="https://www.covid19oralrx-hcp.com/">https://www.covid19oralrx-hcp.com/</a></td>
</tr>
<tr>
<td>Pfizer Medical</td>
<td>1-800-438-1985</td>
</tr>
<tr>
<td>Description</td>
<td>Details</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Administration Type</td>
<td>Intramuscular Injection</td>
</tr>
<tr>
<td>Availability</td>
<td>Providers enrolled to provide Evusheld can email <a href="mailto:therapeutics@dshs.Texas.gov">therapeutics@dshs.Texas.gov</a> to request cartons. 1 carton = 150 mg tixagevimab plus 150 mg cilgavimab. Requested quantities must be in multiples of 24 cartons.</td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>Please report inventory and administration in HPOP daily by cartons (150 mg tixagevimab/150 mg cilgavimab). The patient receiving the larger initial dose (300 mg each of tixagevimab/cilgavimab) would be reported as TWO units (cartons or courses) administered while the repeated, smaller dose (150 mg tixagevimab/150 mg cilgavimab) would be reported as ONE unit administered. Patient-level reporting to ImmTrac within 30 days of administration</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resource</th>
<th>Link/Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider Fact Sheet</td>
<td><a href="https://www.fda.gov/media/154701/download">https://www.fda.gov/media/154701/download</a></td>
</tr>
<tr>
<td>FDA FAQ</td>
<td><a href="https://www.fda.gov/media/154703/download">https://www.fda.gov/media/154703/download</a></td>
</tr>
<tr>
<td>Evusheld Webpage</td>
<td><a href="https://www.evusheld.com/splash.html">https://www.evusheld.com/splash.html</a></td>
</tr>
<tr>
<td>Astrazeneca Contact</td>
<td>1-800-236-9933</td>
</tr>
</tbody>
</table>
Sotrovimab

**Description**
- **Details**
- **Manufacturer**: GlaxoSmithKline (GSK)
- **Administration Type**: Intravenous Infusion (IV)
- **Order Pack Sizes**: 12 patient courses: Providers must request Sotrovimab in multiples of 12 courses.
- **Availability**: Providers are currently able to request allocations of Sotrovimab in VAOS. For guidance on placing a request, see the Allocation Guide.
- **Reporting Requirements**
  - For Hospitals: Weekly reporting to TDEM of courses on-hand and administered.
  - For Non-Hospitals: Weekly reporting to HHS Teletracking of courses on-hand and administered.
  - For All: Patient-level data within 30 days of administration to ImmTrac2.

**Summary Authorization Statement**


**Resource Link/Contact**
- **Provider Fact Sheet**: [https://www.fda.gov/media/149534/download](https://www.fda.gov/media/149534/download)
- **Patient Fact Sheet (English)**: [https://www.fda.gov/media/149533/download](https://www.fda.gov/media/149533/download)
- **GSK Sotrovimab Site**: [https://www.sotrovimab.com/?cc=ps_WX47F4UZG81040671&mcm=300000&gclid=76b80e837c9f1fa7c4526fd8512974e1&gclsrc=3p.ds&](https://www.sotrovimab.com/?cc=ps_WX47F4UZG81040671&mcm=300000&gclid=76b80e837c9f1fa7c4526fd8512974e1&gclsrc=3p.ds&)
- **GSK COVID Contact Center**: 1-866-475-2684

**NO LONGER AUTHORIZED
NO LONGER AVAILABLE FOR ORDERING**
Bamlanivimab plus Etesevimab

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td>Administration Type</td>
<td>Intravenous Infusion (IV)</td>
</tr>
<tr>
<td>Availability</td>
<td>Bam/Ete is paused for allocation requests in VAOS. For more information, please view the most recent <a href="https://www.dhs.gov/emergency-preparedness-and-response/national-infrastructural-regulatory-and-policy-framework/emergency-use-authorization#:~:text=bamlanivimab%20(ASPR),Bamlanivimab%20administered">DSHS communication</a></td>
</tr>
<tr>
<td>Reporting Requirements</td>
<td>For Hospitals: Weekly reporting to TDEM of courses on-hand and administered For Non-Hospitals: Weekly reporting to HHS Teletracking of courses on-hand and administered An Administrator's Report of administration form available.</td>
</tr>
</tbody>
</table>


Provider Fact Sheet: [https://www.fda.gov/media/145802/download](https://www.fda.gov/media/145802/download)

Patient Fact Sheet (English): [https://www.fda.gov/media/145803/download](https://www.fda.gov/media/145803/download)

Patient Fact Sheet (Spanish): [https://www.fda.gov/media/148713/download](https://www.fda.gov/media/148713/download)

Eli Lilly Bam/Ete Site: [https://www.covid19.lilly.com/bam-ete](https://www.covid19.lilly.com/bam-ete)

Lilly COVID Hotline: 1-855-545-5921
REGEN-COV

NO LONGER AUTHORIZED
NO LONGER AVAILABLE FOR ORDERING

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Regeneron</td>
</tr>
<tr>
<td>Administration Type</td>
<td>Intravenous Infusion (IV) or subcutaneous injection (SQ)</td>
</tr>
<tr>
<td>Availability</td>
<td>Bam/ete is paused for allocation requests in VAOS. For more information, please view the most recent DSIS communication</td>
</tr>
</tbody>
</table>
| Reporting Requirements    | For Hospitals: Weekly reporting to TDEM of courses on-hand and administered For Non-Hospitals: Weekly reporting to HHS Teletracking of courses on-hand and administered
|                          | Provider Fact Sheet                                                    | https://www.fda.gov/media/145802/download |
| Patient Fact Sheet (English) | https://www.fda.gov/media/145803/download                                |
| Patient Fact Sheet (Spanish) | https://www.fda.gov/media/148713/download                                |
| FAQ                       | https://www.regencov.com/hcp/resources/faq                             |
| Regeneron Medical Information | 1-844-734-6643                                                          |
No Cost to Therapeutics Providers

US HHS has purchased these therapeutics and they are provided to facilities at no cost. Providers may not charge for the medication itself. Providers can seek reimbursement for the administration or dispensing of the therapeutics.
Provider Mandatory Reporting

Medication Errors & Serious Adverse Events

• Submit adverse event reports to FDA MedWatch using one of the following methods:
  • Complete and submit the report online: [www.fda.gov/medwatch/report.htm](www.fda.gov/medwatch/report.htm), or
  • Complete and submit a postage-paid FDA Form 3500 ([https://www.fda.gov/media/76299/download](https://www.fda.gov/media/76299/download)) and return by:
    • Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
    • Fax (1-800-FDA-0178), or
    • Call 1-800-FDA-1088 to request a reporting form.
• In addition, please provide a copy of all FDA MedWatch forms to the appropriate therapeutic manufacturer:

<table>
<thead>
<tr>
<th>Therapeutics Manufacturer’s Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bam/Ete - Eli Lilly and Company, Global Patient Safety</strong></td>
</tr>
</tbody>
</table>
| Fax: 1-317-277-8653  
| Email: maildata.gspmsd4@lilly.com  
| Or call Eli Lilly and Company at 1-855-Lilly219 (1-855-545-5921) |
| **Regen-COV - Regeneron Pharmaceuticals** |
| Fax: [BAM/ELE, REGEN-COV, and Sotrovimab NO LONGER AUTHORIZED](https://www.fda.gov/media/76299/download)  
| E-mail: medical.information@regeneron.com  
| Or call Regeneron Pharmaceuticals at 1-844-734-6643 |
| **Sotrovimab – GlaxoSmithKline, Global Safety** |
| Fax: 919-287-2902  
| Email: WW.GSKaereportingUS@gsk.com  
| Or call GSK COVID contact center at 1-866-GSK-COVID (866-475-2684) |
| **Lilly - Bebtelovimab** |
| Call: 1-855-545-5979  
| Website: [https://www.covid19.lilly.com/bebtelovimab/hcp](https://www.covid19.lilly.com/bebtelovimab/hcp) |
| **Paxlovid - Pfizer Safety** |
| Fax: 1-800-438-1985  
| Website: [https://www.pfizersafetyreporting.com/#/en](https://www.pfizersafetyreporting.com/#/en)  
| Or call Pfizer Safety at 1-866-635-8337 |
| **Evusheld - AstraZeneca** |
| Fax: 1-866-742-7984  
| Website: [https://contactazmedical.astrazeneca.com](https://contactazmedical.astrazeneca.com)  
| Or call AstraZeneca safety at 1-800-236-9933 |
| **Molnupiravir - Merck** |
| Fax: 215-616-5677  
| E-mail: dpoc.usa@msd.com  
| For voluntary pregnancy reporting: 1-877-888-4231 or pregnancyreporting.msd.com (Requires agreement from patient and provider) |
Providers must report the amount **administered**/dispensed since last entry (which should be the day before) and current **on hand** amounts for each product for Paxlovid, molnupiravir, Evusheld, and bebtelovimab to **HPOP daily**. Providers can find a help guide for HPOP here: [Oracle HPoP Provider Portal - Get Started](#). Evusheld must be reported by cartons (150 mg tixagevimab/150 mg cilgavimab).

**Reporting of sotrovimab remains in the old reporting systems.** Hospitals must report administration and courses on hand for sotrovimab into **TDEM** portal daily. Non-hospitals must report to **HHS TeleTracking**.

All providers are required to report administration of COVID-19 therapeutics to ImmTrac2 within 30 days of administration.

---

**Reporting Requirements**

<table>
<thead>
<tr>
<th>Hospital *</th>
<th>Molnupiravir, Paxlovid, Bebtelovimab, and/or Evusheld</th>
<th>Sotrovimab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HPOP, ImmTrac2</td>
<td>TDEM, ImmTrac2</td>
</tr>
</tbody>
</table>

**Non-Hospital**

<table>
<thead>
<tr>
<th></th>
<th>HPOP, ImmTrac2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Teletracking, ImmTrac2</td>
</tr>
</tbody>
</table>

* A facility is considered a “Hospital” for DSHS reporting purposes if they are mandated to report per the [HHS per the CMS CoP](#).

Reporting is required. Adherence to reporting requirements is crucial, as it affects the allocations the state receives.
Provider Tools
Providers can use the New US HHS COVID-19 Therapeutics locator to find locations with available Paxlovid, Molnupiravir, Evusheld, Bebtelovimab, and Sotrovimab.

Reference Guides

Providers may refer to the following resources for more specific guidance:

- **Therapeutics Webpage**
  - For most therapeutics updates and resources.

- **COVID-19 Therapeutics Allocation Request Guide**
  - For a walkthrough of how to place an allocation request for therapeutics in VAOS.

- **COVID-19 Therapeutics Enrollment Guide**
  - For how to enroll as a therapeutics provider.

- **Therapeutics FAQ**
  - For more detailed answers to common questions.

- **FAQ for COVID-19 Therapeutics Providers**
  - Monoclonal Antibodies Overview
  - From the CDC: Therapeutics are drugs to help treat and care for patients, who, in this case, are diagnosed with COVID-19 or exposed to COVID-19.
  - Early treatment of any disease can help avert progression to more serious illness, especially for high-risk patients.

- **VAXOS Catalog**
  - For a list of guides on specific VAOS actions.

- **COVID-19 Vaccine Job Aids**
  - VAOS Tips & Tricks (11/2/2021)
  - COVID-19 Vaccine Data
  - Dashboard (11/2021)

- **COVID-19 Therapeutics Job Aids**
  - COVID-19 THERAPEUTICS

- **VAXOS Catalog**
  - For a list of guides on specific VAOS actions.

- **HPOP FAQ**
  - For answers specific to HPOP.